July 10 – Interim report April – June 2025
Alligator hosted a webinar on Thursday, 10 July, at 3 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the report, which was followed by a Q&A session.
The call was held in English and can be requested through the link below.
LATEST NEWS
Alligator Bioscience comments on Henlius dosing first patient in the US in Phase 3 trial of HLX22 in gastric cancer
Lund, Sweden – 14 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henl …
Alligator Bioscience AB reports financial results for Q2 2025 and provides a business update
GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 …
Alligator to present 24-month OPTIMIZE-1 data at ESMO GI 2025
Lund, Sweden, 1 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical- …